Italian law enforcement authorities are currently investing the theft. However, the situation goes beyond EU and national current practices for handling quality or product defects; these are extraordinary circumstances driven by criminal activities that require special measures and strong collaboration from authorities across the EU.
Jacques Servier, the founder of France's second-largest pharmaceutical group who became ensnared...
The European Medicines Agency (EMA) has been informed that vials of the cancer medicine...
BioAlliance Pharma SA and Topotarget A/S today announced their intention to merge to create an...
The BBC reports that pharmaceutical company GlaxoSmithKline is accused of bribing doctors to prescribe medicines in Poland. A "Panorama" show to air Monday evening quotes a former sales representative for the company saying doctors there were paid to prescribe its drugs.
Moberg Pharma AB has entered into a definitive agreement with Oracain II Aps (Denmark) to acquire all assets and global rights to a novel and patent pending oral formulation of the proven substance bupivacaine, for the treatment of pain in the oral cavity.
Will Sun’s latest acquisition change the global pharma landscape, or result in yet another problem-filled “me too” pharma company?
Oramed Pharmaceuticals Inc., a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that the Intellectual Property Department of Hong Kong has granted the Company's patent for its invention, titled "Methods and Compositions for Oral Administrations of Proteins."
Swedish drug company Meda has rebuffed an approach from generic drug maker Mylan which was looking to combine the two businesses. Meda AB says talks between the two companies have stopped "without further actions."
Gilead Sciences has announced topline results from a Phase 3 clinical trial (Study GS-US-334-0118) in Japan evaluating the once-daily nucleotide analog polymerase inhibitor sofosbuvir in combination with ribavirin (RBV) for the treatment of genotype 2 chronic hepatitis C virus (HCV) infection.
Actavis has announced the official opening of its new regional office in Singapore that will serve as the headquarters for the company's Asia Pacific and Africa (APACA) region.
Novartis Pharma K.K. said Thursday its president Yoshiyasu Ninomiya and two other top executives have resigned to take responsibility for its employees' inappropriate involvement in a clinical study led by medical doctors.
The U.S. Food and Drug Administration has approved the first tablet for gradually reducing hay fever allergy symptoms, an alternative to uncomfortable allergy-desensitizing shots.
Evotec AG has announced a research collaboration and licensing deal with Debiopharm Group Lausanne, Switzerland. The objective of this collaboration is to identify and develop novel compounds having the potential to treat multiple forms of solid tumors and leukemias with defined genetic alterations.
Actavis today announced that it has acquired Silom Medical Company, a privately held generic pharmaceutical company focused on developing and marketing therapies in Thailand, for approximately $100 million in cash.
Evotec AG today announced that it has entered into a research alliance with Panion Ltd, a subsidiary of Convergence Pharmaceuticals Holdings Ltd. Convergence is a UK company focused on the development of novel, high value analgesics to treat chronic pain.
England's public health agency says two people have caught tuberculosis from a pet cat, the first time the bacterial disease has been documented to spread from cat to human.
Astellas Pharma Inc. has obtained marketing approval of their oral androgen receptor signaling inhibitor, XTANDI capsules 40mg for the treatment of patients with castration-resistant prostate cancer in Japan.
AstraZeneca today announced that the Japanese Ministry of Health, Labour and Welfare (MHLW) approved FORXIGA® (dapagliflozin in 5 and 10 mg tablets), a sodium-glucose cotransporter 2 (SGLT2) inhibitor, as a once-daily oral treatment for type 2 diabetes.
A polio-free India is one of the biggest global public health achievements of recent times.
Shares of Endocyte nearly doubled in value Friday after European Union regulators said the company's drug Vynfinit should be approved as a treatment for ovarian cancer.
Otsuka Pharmaceutical Co. has become the first company in the world to obtain regulatory approval for a pharmacological treatment of autosomal dominant polycystic kidney disease (ADPKD).
Horizon Pharma Inc. will acquire Vidara Therapeutics for a "tax-efficient corporate structure."
Idenix Pharmaceuticals has filed patent infringement lawsuits against Gilead Sciences and/or certain of its subsidiaries in each of three countries - France, Germany and the United Kingdom.
Intrexon Corporation, a synthetic biology company, has acquired state-of-the-art laboratory operations in Budapest, Hungary from Codexis, Inc., a developer of biocatalysts for the pharmaceutical and complex chemistry industries.
Applikon Biotechnology will open a new production facility on Wednesday March 19th in Guangzhou, China. The opening ceremony will be combined with a scientific seminar “Innovations in bioreactor technology”.
Chiesi Farmaceutici SpA, an international pharmaceutical company focused in the respiratory, neonatology and special care therapeutic areas, closed 2013 with a turnover of more than 1,236 million euro, an increase of 11.8% compared to 2012 (+14% at constant exchange rates).
AstraZeneca today announced the sale of its Alderley Park site in Cheshire, UK, to Manchester Science Parks (MSP), a Greater Manchester based public-private partnership and science park operator.
With the merger, the company extends its global footprint to include 20 operational offices in 15 countries, including new offices in Taiwan, China, Hong Kong, South Korea, Vietnam, Singapore, and Malaysia.
- Page 1